Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Matias Ferraris"'
Autor:
Ronan Mahon, Santosh Tiwari, Mirja Koch, Matias Ferraris, Keith A Betts, Yan Wang, Sophie Gao, Pascal Proot
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 3 (2024)
Aim: To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison. Methods: Patients from two phase II/III trials for erenuma
Externí odkaz:
https://doaj.org/article/410b4842f364416c8d66e4061907ba36
Autor:
Stewart J. Tepper, Juanzhi Fang, Pamela Vo, Ying Shen, Lujia Zhou, Ahmad Abdrabboh, Mrudula Glassberg, Matias Ferraris
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the
Externí odkaz:
https://doaj.org/article/edb867d28064473db2f7c37ae16d9c26
Autor:
Siriporn Wongsiriroj, Elisabetta Grillo, Sabrina Levi, Ronald Zielman, Elia Lahouiri, Marco Marchina, Marco Pedrazzoli, Matias Ferraris
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 551-565 (2020)
Abstract Introduction The parent study was a survey in 28 headache centers (6 countries) which identified five potential root causes for long waiting lists that limit patient access to specialist care. Here we performed an extension of the parent stu
Externí odkaz:
https://doaj.org/article/e41b9417f518449b931d62b296cb55c1
Autor:
Stewart J Tepper, Juanzhi Fang, Lujia Zhou, Pamela Vo, Ahmad Abdrabboh, Mrudula Glassberg, Matias Ferraris
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-spe
Externí odkaz:
https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f
Autor:
Ronan Mahon, Pamela Vo, Katharina Pannagl, Santosh Tiwari, Harald Heemstra, Matias Ferraris, Jing Zhao, Keith A. Betts, Pascal Proot
Publikováno v:
Current medical research and opinion. 39(1)
To assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM) and present de-novo indirect treatment comparisons (ITCs) based on available clinical trial data.We conducted ITCs based on results fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3784873c184fb5c996006dc404eba1
https://pubmed.ncbi.nlm.nih.gov/36189948
https://pubmed.ncbi.nlm.nih.gov/36189948
Autor:
Juanzhi Fang, Pamela Vo, Lujia Zhou, Stewart J. Tepper, Mrudula Glassberg, Ying Shen, Matias Ferraris, Ahmad Abdrabboh
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1157-1170
BACKGROUND: Migraine is a common neurological disease that can have a substantial impact on patients' lives and on society. Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, was specifically develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ccadd649f63f8b3182cd2dbed7c16dc
https://doi.org/10.18553/jmcp.2021.21060
https://doi.org/10.18553/jmcp.2021.21060
Autor:
Juanzhi Fang, Ahmad Abdrabboh, Matias Ferraris, Lujia Zhou, Stewart J. Tepper, Mrudula Glassberg, Ying Shen, P. Vo
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-12 (2021)
The Journal of Headache and Pain
The Journal of Headache and Pain
Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bcc99fcb12fd38028fdd8f7d227c9b
https://doaj.org/article/edb867d28064473db2f7c37ae16d9c26
https://doaj.org/article/edb867d28064473db2f7c37ae16d9c26
Autor:
Matias Ferraris, R. G. Shah, Mark A Cheadle, Juanzhi Fang, Stephanie Korrer, Cristina Lopez-Lopez, Jonathan C Johnson
Publikováno v:
Advances in Therapy. 38:2921-2934
This retrospective analysis aimed to characterize patients with migraine initiating erenumab and the shifting or trend of patient characteristics over time in a real-world setting. Adult patients with at least one erenumab written prescription/admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8073406568eaefa77a0a16137606b35
https://doi.org/10.1007/s12325-021-01677-y
https://doi.org/10.1007/s12325-021-01677-y
Autor:
Elisabetta Grillo, Matias Ferraris, Elia Lahouiri, Sabrina Levi, Siriporn Wongsiriroj, Ronald Zielman, Marco Pedrazzoli, Marco Marchina
Publikováno v:
Neurology and Therapy
Neurology and Therapy, Vol 9, Iss 2, Pp 551-565 (2020)
Neurology and Therapy, Vol 9, Iss 2, Pp 551-565 (2020)
Introduction The parent study was a survey in 28 headache centers (6 countries) which identified five potential root causes for long waiting lists that limit patient access to specialist care. Here we performed an extension of the parent study to inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2508f6099cf45fbc059f1a81cb81e376
http://europepmc.org/articles/PMC7606425
http://europepmc.org/articles/PMC7606425
Autor:
Juanzhi Fang, Stewart J. Tepper, P. Vo, Lujia Zhou, Ahmad Abdrabboh, Matias Ferraris, Mrudula Glassberg
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac04eaab8bbda6f7608e9685cbaf94cc
https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f
https://doaj.org/article/c34ea09e7919453a84bd75c1b089350f